Entera Story

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;'>EB</div>
Lets try to break down the odds of Entera Bio to fully recover from the current slide as its shares went up 0.90%. Entera Bio's current daily volatility is 4.78 percent, with a beta of -0.11 and an alpha of -0.28 over DOW. While many traders are getting carried away by overanalyzing pharmaceutical products, it is reasonable to break down Entera Bio. We will evaluate if Entera Bio shares are reasonably priced going into December.
Published over a week ago
View all stories for Entera Bio | View All Stories
Chances of Entera Bio to slide after the volatility rises
Entera Bio currently holds roughly 9.77 M in cash with (11.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.54. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Entera Bio has an asset utilization ratio of 2.7 percent. This suggests that the company is making $0.027 for each dollar of assets. An increasing asset utilization means that Entera Bio is more efficient with each dollar of assets it utilizes for everyday operations.

How important is Entera Bio's Liquidity

Entera Bio financial leverage refers to using borrowed capital as a funding source to finance Entera Bio ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Entera Bio financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Entera Bio's total debt and its cash.

How Entera utilizes its cash?

To perform a cash flow analysis of Entera Bio, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Entera Bio is receiving and how much cash it distributes out in a given period. The Entera Bio cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Entera Bio Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Entera Bio reported Net Cash Flow from Operations of (8.92 Million) in 2019

A Deeper Perspective

Entera Bio secures Sharpe Ratio (or Efficiency) of -0.0446, which denotes the company had -0.0446% of return per unit of risk over the last month. Macroaxis standpoint towards predicting the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Entera Bio exposes twenty-six different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to confirm Entera Bio coefficient of variation of (1,760), and Mean Deviation of 3.23 to check the risk estimate we provide.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Will price continue to rise in December 2020?

The kurtosis is down to 10.73 as of today. Entera Bio exhibits very low volatility with skewness of 2.09 and kurtosis of 10.73. However, we advise investors to further study Entera Bio technical indicators to make sure all market info is available and is reliable. Entera Bio is a potential penny stock. Although Entera Bio may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Entera Bio. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Our Final Perspective on Entera Bio

While few other entities under the biotechnology industry are still a bit expensive, Entera Bio may offer a potential longer-term growth to investors. The bottom line, as of the 19th of November 2020, we believe that at this point, Entera Bio is dangerous with very small odds of distress within the next 2 years. From a slightly different point of view, the entity appears to be undervalued. Our primary 30 days 'Buy-vs-Sell' recommendation on the company is Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Entera Bio. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com